SCHEDULE 2 - Luxembourg Date of publication: 28-June-2023														
	Full Name	Full Name HCPs: City of Principal Practice Country of Principal Practice HCOs: city where registered Practice Practice Address Unique country identifier OPTIONAL					Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)		publication: 2	20-June-2023	
	(Art. 1.01)	(Art. 3)	(Schedule 1)	(Art. 3)	(Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.a)	Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	су	TOTAL OPTION AL	
	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriately													
σ													0	
HCPs	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02					N/A	N/A	0		0	0		0	
	Number of Recipients in aggregate disclosure - Art. 3.02 % of the number of Recipients included in the aggregate disclosure in the total number of Recipients					N/A N/A	N/A N/A	0		0	0		0 N/A	
	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
s													0	
HCOs		OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02						0			0			0	
	Number of Recipients in aggregate disclosure - Art. 3.02 % of the number of Recipients included in the aggregate disclosure in the total number of Recipients						0			0			0	
	% of the number of R	ecipients included in ti	ne aggregate disclosui	e in the total number o	or Recipients		0%		J	0%			N/A	
۵		AGGREGATE DISCLOSURE												

Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1